BBIO Earnings Bridgebio Pharma, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–27 of 27
| Q3 2026 | 2026-09-30 | -0.42 | 2026-10-29 | 10-Q |
| Q2 2026 | 2026-06-30 | -0.78 | 2026-08-10 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.84 | 2026-05-07 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -1.00 | 2026-02-24 | 10-K |
| FY 2025 | 2025-12-31 | -3.78 | 2026-02-24 | 10-K |
| Q3 2025 | 2025-09-30 | -0.95 | 2025-10-29 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.95 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | -0.88 | 2025-04-29 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -1.43 | 2025-02-20 | 10-K |
| FY 2024 | 2024-12-31 | -2.88 | 2025-02-20 | 10-K |
| Q3 2024 | 2024-09-30 | -0.86 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -0.39 | 2024-08-01 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.20 | 2024-05-02 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -0.97 | 2024-02-22 | 10-K |
| FY 2023 | 2023-12-31 | -3.95 | 2024-02-22 | 10-K |
| Q3 2023 | 2023-09-30 | -1.08 | 2023-11-02 | 10-Q |
| Q2 2023 | 2023-06-30 | -0.98 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -0.92 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -0.91 | 2023-02-23 | 10-K |
| FY 2022 | 2022-12-31 | -3.26 | 2023-02-23 | 10-K |
| Q3 2022 | 2022-09-30 | -0.93 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -0.07 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -1.35 | — | — |
| FY 2021 | 2021-12-31 | -3.90 | — | — |
| Q3 2021 | 2021-09-30 | -1.06 | — | — |
| Q2 2021 | 2021-06-30 | -0.66 | — | — |
| FY 2020 | 2020-12-31 | -3.80 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.